Skip to content

MEDIGENA

Active Private limited companyfounded 2023active for 3 yearsChaussée de Namur, Natoye 73, 5360 HamoisKBO/BCE: BE 0803.437.439 subsidiary of

Lifetime

3 annual accounts with figures on one time axis
peak of €120,045 in 2024
€88,886▼ 26.0%
peak of €54,065 in 2024
€14,379▼ 73.4%
peak of €35,940 in 2024
€30,000▼ 16.5%
€458,155▼ 14.1%
Board2 names since 2023
2 directors and 1 other
Owners
100%
Documentsfilings and deeds
09-08-20269 days late
2025micro format
Gross margin from €120,045 to €88,886Result from €54,065 to €14,379Dividend €11,840Equity from €35,940 to €30,000

Key points

from the 2025 annual accounts

Equity

€30,000 ▼ 16.5%
35,9402024+14,379Profit-11,840Dividend-8,480Other30,0002025

MEDIGENA paid out €11,840 in dividends. That is 82% of the 2025 profit.

Turnover

≈ €200,000 estimated

The micro format states no turnover.

Debts

€458,155 94% of the balance sheet
Financial debts 81%Suppliers 3%Other 16%

Of this, €82,090 falls due within a year.

Filings

3 annual accounts 3 late
AprilJune31 JulyOctober202320242025

The 2023 accounts came in latest, 24 days after the end of the period.

Position in the sector

6.1%

Lower solvency than 88% of companies in human health. The sector median is 63.1%, over 21,373 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 1,514 companies had the same profile as MEDIGENA has now. Each dot stands for 4 companies, two years later.

95.8%
were still trading
1.6%
stopped another way
2.4%
went bankrupt
  • Small
  • 2 to 5 years old
  • solvency under 10%
  • a profit under 5% of the balance sheet

Another 0.2% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 1,514 companies, not a prediction for MEDIGENA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 29-06-2023
Director, since 29-06-2023
  • 100%score equity €482,616 (2025) · annual accounts 2025 of
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0803437439
Publication in the Belgian Official Gazette Gazette deed
Incorporation Founding capital of €30,000 · Founded by · (director) and (director) appointed · published on 04-07-2023 · Gazette deed
First establishment Chaussée de Namur, Natoye 73, Hamois
All 8 events

Comparable companies

same main activity, similar in size and age
Company
MEDIGENA Hamois €488,155 €88,886 6.1% -
Vasculart Medical Forest €515,186 €91,656 10.5% -
CENTRE MEDICAL DR. TRUSCA Namur €547,831 €99,344 50.0% -
Dr Milie Nwoye Gynecology Tervuren €512,618 €95,809 6.4% -
Cabinet Médical du Docteur Françoise POTTIER Chaudfontaine €498,969 €117,456 25.6% -
MEDFOIL Ixelles €425,208 €96,495 51.5% -
CABBA MEDICAL Sint-Gillis (bij-Brussel) €420,011 €111,620 16.6% -

These companies have the same main activity as MEDIGENA: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €420,000 and €548,000, founded between 2021 and 2024.

Official details

Source: KBO
Status
Active since 30-06-2023Normal situation
Activity
Specialist medical practiceNACE 86220
Establishment unit
2.350.354.5405360 Hamois, since 30-06-2023
Financial year end
31 December
Peppol
Reachable since 17-11-2025
Company details

Annual accounts 2025

€488,155▼ 14.2%
Filing
Filed on 09-08-2026
Financials

Insights on MEDIGENA

MEDIGENA files the micro format. That format states no turnover. The gross margin rose from €41,007 in 2023 to €88,886 in 2025.

holds all the shares.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about MEDIGENA

What is the company number of MEDIGENA?
The company number of MEDIGENA is 0803.437.439. The VAT number is the same number with BE in front: BE 0803.437.439.
Where is MEDIGENA based?
The registered office is at Chaussée de Namur, Natoye 73, 5360 Hamois.Company details
What does MEDIGENA do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of MEDIGENA?
MEDIGENA is a private limited company (BV).
When was MEDIGENA founded?
MEDIGENA was founded on 30-06-2023.
Is MEDIGENA still active?
Yes, MEDIGENA is an active enterprise in the KBO register.
What is the turnover of MEDIGENA?
The turnover in financial year 2025 is about €200,000. This figure is estimated from the gross margin of €88,886 and 33 comparable companies (NACE 862). It probably lies between €150,000 and €250,000.Financials
Is MEDIGENA profitable?
In financial year 2025, MEDIGENA made a profit of €14,379.
Where can I find the annual accounts of MEDIGENA?
MEDIGENA filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of MEDIGENA due?
MEDIGENA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.